Retirement Systems of Alabama Sells 1,145 Shares of Stryker Co. (NYSE:SYK)

Retirement Systems of Alabama reduced its position in Stryker Co. (NYSE:SYK) by 1.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 74,282 shares of the medical technology company’s stock after selling 1,145 shares during the quarter. Retirement Systems of Alabama’s holdings in Stryker were worth $26,745,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Alhambra Investment Management LLC increased its holdings in Stryker by 1.5% in the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock valued at $719,000 after buying an additional 29 shares during the period. Capital & Planning LLC grew its holdings in shares of Stryker by 3.6% during the 4th quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock valued at $304,000 after purchasing an additional 29 shares during the last quarter. Concord Wealth Partners increased its position in Stryker by 2.2% during the 4th quarter. Concord Wealth Partners now owns 1,396 shares of the medical technology company’s stock worth $503,000 after purchasing an additional 30 shares in the last quarter. Avestar Capital LLC increased its position in Stryker by 1.1% during the 3rd quarter. Avestar Capital LLC now owns 2,948 shares of the medical technology company’s stock worth $1,065,000 after purchasing an additional 31 shares in the last quarter. Finally, Union Savings Bank increased its position in Stryker by 1.0% during the 4th quarter. Union Savings Bank now owns 3,162 shares of the medical technology company’s stock worth $1,138,000 after purchasing an additional 31 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Trading Up 1.7 %

NYSE:SYK opened at $399.01 on Thursday. The firm’s fifty day moving average is $376.87 and its 200-day moving average is $364.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 52 week low of $314.93 and a 52 week high of $406.19. The firm has a market cap of $152.11 billion, a P/E ratio of 51.42, a P/E/G ratio of 2.78 and a beta of 0.96.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the firm earned $3.46 EPS. Equities analysts expect that Stryker Co. will post 13.5 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.84%. Stryker’s dividend payout ratio is presently 43.30%.

Insider Buying and Selling

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 5.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of research analyst reports. UBS Group upped their price objective on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. Robert W. Baird upped their price objective on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Citigroup upped their price objective on shares of Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. The Goldman Sachs Group upped their price objective on shares of Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research report on Thursday, January 30th. Finally, JMP Securities reissued a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $419.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.